LUZP1

Across TCGA pan-cancer cohorts, LUZP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LUZP1 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LUZP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LUZP1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where LUZP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	15	view →
GBM	DFS	Tertile	All	0.283	0.461	.048	2	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	2	view →
LSCC	DFS	Median	All	0.461	0.861	.028	2	view →
LUAD	OS	Median	III,IV	0.259	0.717	.038	2	view →
CCRCC	DFS	Quartile	III,IV	0.785	0.426	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LUZP1–PDAC (DFS)

Open the PDAC breakdown →